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A Workhorse
and a Thoroughbred

Next-Gen
Sequencing

Dean’s Message

Research

Momentum Is Strong

Vitamin D Low, Blood Pressure High?

T

alk about progress: a
massive effort that took
10 years to complete
just a decade ago can now be
accomplished in a matter of
days. I’m talking about the
sequencing of RNA expression
and the speed and precision of
“next generation” technologies
like our powerhouse, the
Illumina® Genome Analyzer. As
you will see in our lead story,
next generation technologies
recently helped researchers
publish two major papers in
RNA and Cell.

This is a source of great pride for
the UConn School of Medicine
and a powerful reminder of how
fortunate we are to be educators
during a time of such profound
growth and discovery.
Every day, the momentum
and energy of our school, our
students and our faculty is felt
in Connecticut and beyond.
In this issue, you will also
learn about achievements of
our faculty across a broad
range of medical specialties
from angiogenesis and gene

therapy to novel approaches to
prevent high blood pressure and
advocacy for cancer survivors.
As always, please do not
hesitate to share your thoughts
about medical education with
me at laurencin@uchc.edu or
by calling 860-679-2594.
Sincerely,

Cato T. Laurencin, M.D., Ph.D.
Vice President for Health Affairs
Dean, UConn School of Medicine

Health Center Researchers Find Combination
Gene Therapy Effective in Healing Hearts

out that even though spores may be genetically identical…
they don’t all behave identically,” says Setlow. During
germination, spore number one may come back to life in
5 minutes but spores two, three and four may take their
time and not germinate for 30 minutes, 24 hours or up
to a month. Setlow says that’s where the problem arises.
For example, if you’re being treated for anthrax, how long
should you take antibiotics – for a week? Then the spore
that germinates in two weeks might kill you.

Grants

Health Center Researcher
Awarded Multimillion Dollar
Department of Defense Grant

B

acterial spores can be nasty. Just ask Peter
Setlow, Ph.D., a professor in the Department
of Molecular, Microbial and Structural
Biology, who has been studying them for over
40 years. He’ll tell you that spores, such as those
of Bacillus anthracis, can cause anthrax. Other
Peter Setlow, professor in the Department of Molecular, Microbial and Structural Biology
bacterial spores are to blame for deadly cases of
food poisoning, botulism, and life-threatening
infections that are especially hazardous to hospitalized patients.
to kill. Our research goal is to better understand the mechanisms
Setlow heads a team of researchers who have been awarded a
that spur them to come out of their dormant phase and spring
multimillion dollar grant from the Department of Defense to
back to life.”
uncover some of the secrets of spores and potentially make them
The award is for $1.25 million per year for a total of five years
less dangerous.
and is a Multidisciplinary University Research Initiative (MURI)
“The vegetative organisms cause the disease but it’s the spores
grant designed to support basic science and/or engineering
that transmit the disease,” explains Setlow. “When they are
research at U.S. institutions of higher education that are of
dormant, they’re very resistant and can survive all kinds of harsh
critical importance to national defense.
chemical treatments, extremes of temperature and low-nutrient
Along with focusing on the mechanisms of spore germination,
environments. However, once the spores germinate, they are easy
Setlow and his team are studying their heterogeneity. “It turns

UConn School of Medicine

V

itamin D is known to be important to bone health, but what about heart
health? UConn Health Center physician-scientists are looking into a
possible link between vitamin D deficiency and high blood pressure.
“Often patients don’t realize they have a vitamin D deficiency, or are unaware
of its relationship with health problems other than bone disorders,” says the
study’s principal investigator William B. White, M.D., professor of medicine and
hypertension expert in the Pat and Jim Calhoun Cardiology Center.
White and Pooja Luthra, M.D., assistant professor of medicine and an
endocrinologist in the New England Musculoskeletal Institute, are recruiting
patients with a diagnosis of treated or untreated high blood pressure and a low William B. White, M.D., and Pooja Luthra, M.D.
vitamin D level.
In the 14-week, double-blind, randomized trial, participants will receive either vitamin D supplements or an enzyme blocker that
targets renin, which is produced in the kidney. They then will get both medications in combination. Their blood pressure will be
monitored both in the office setting and out of the office using a 24-hour ambulatory blood pressure monitor.
The UConn Health Center study is supported by an independent $480,000 investigator-initiated grant from Novartis
Pharmaceuticals, Inc., in East Hanover, N.J., over the next three years. n

u

R

esearchers in the Molecular Cardiology and Angiogenesis
Laboratory have found that damaged diabetic hearts can be
repaired using combination gene therapy.
Nilanjana Maulik, Ph.D., professor in the Department of
Surgery, found in preclinical studies that adenoviral VEGF
(vascular endothelial growth factor) and Ang-1 (angiopoietin-1)
increased blood flow and the heart’s ability to pump more
effectively. The study is published in Diabetes, a journal of the
American Diabetes Association.
“In diabetes, there is impairment of myocardial angiogenesis –
decreased vessel formation in the heart which leads to decreased
blood flow and eventually to heart failure,” explains Maulik. The
decrease in blood vessel formation is mainly due to the imbalance
in growth factors such as VEGF and Ang-1.
Scientists have long studied ways in which gene therapy could
be used to repair the damaged diabetic heart. Most of the studies
have focused on using a single gene as the therapeutic agent.
Maulik decided to focus on a combination gene therapy which
proved to be the key.
In animal studies, diabetic hearts damaged by myocardial
infarctions were injected with a mixture of VEGF and Ang-1.
Thirty days later, heart function was measured using an
echocardiogram. The hearts subjected to this therapy performed
better than the untreated hearts. “We observed reduced fibrosis
and increased capillary and arteriolar density in the treated
diabetic hearts compared to the diabetic hearts that were not
treated with the combination therapy,” explains Maulik. The next
step is a clinical trial to test the therapy’s effectiveness in humans
with diabetic heart failure. n

“It turns out that even though spores may
be genetically identical...they don’t all
behave identically.”
Setlow believes if his team can figure out why there is
this heterogeneity - why one spore germinates faster than
another - they might be able to figure out a way to get the
spores to all germinate at the same time. An instrument
developed by Ji Yu, Ph.D., in the Center for Cell Analysis
and Modeling is crucial to this research. Instead of studying
whole spore populations, Yu’s apparatus will allow them to
look at one spore at a time, how it germinates differently
from other spores and perhaps how it differs from other
spores in the population.
“If we can better understand this process, maybe we can
figure out ways to subvert it, figure out a better way to kill
the spores,” adds Setlow. “Then there would be big savings
in terms of food quality, energy costs, etc., and medical
treatments for bacterial diseases could be more effective and
potentially life-saving.” n
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Research

Brenton Graveley, Ph.D.,
associate professor
of genetics and
developmental biology

The project resulted in a working draft of the genome in 2000
and a more complete draft three years later. At that point, next
generation sequencers were still a couple years in the future
and, as the adage goes, timing is everything. “Our sequencer can
process more than twice the number of bases in the genome,”
says Graveley, matter-of-factly, “in about five days.” In fact, armed
with the Illumina sequencer, which the Health Center acquired
in the spring of 2008, Graveley’s team has already generated
over 125 billion bases of sequence, more than 40 times the size
of the human genome. And, he notes, “The output is increasing
exponentially.”
Some of those data are included in two papers co-authored
by Graveley and recently accepted for publication in the
prominent journals RNA and Cell. The RNA paper is about
a family of small RNAs that are expressed in planarians
(flatworms) and required for the worms’ well-known ability to
regenerate and for their stem cells to function. The Cell paper
focuses on small RNAs in bacteria that function to defend the
bacteria against invading viruses. They are the first two papers
containing data generated by the Illumina sequencer. But they
are only the vanguard.

Fast Fact

471 Number of scientists

actively involved in biomedical
research at the UConn
Health Center.

Dental Researchers Study Potential Treatment
for Common Chemotherapy Side Effect

D

ouglas Peterson, D.M.D., Ph.D., is leading a team of
researchers who are studying treatments to prevent oral
mucositis in patients undergoing high-dose cancer therapy.
Peterson is a professor of oral medicine in the Department of
Oral Health and Diagnostic Sciences in the School of Dental
Medicine and is also the chair of the Head and Neck/Oral
Oncology Program in the Neag Comprehensive Cancer Center.
Peterson and his team authored a paper that was recently
published in the Journal of Clinical Oncology. The study evaluated
the safety and efficacy of a topical oral spray for the prevention
and treatment of chemotherapy-induced oral mucositis.
Oncology patients may
develop mouth problems during
and following cancer treatment,
including painful mouth ulcers,
infection, taste changes and/or
dryness. Relative to the clinical
trial, a sore, ulcerated mouth is a
frequent side effect of high-dose
chemotherapy and/or head and
neck radiation. The mouth, as well
as the remainder of the digestive
tract, contains lining cells (mucosa)
that are sensitive to several types of cancer therapies. Injury to
these lining cells in the mouth results in oral mucositis, which
can appear as redness (inflammation) and sores (ulcerations). The
condition can lead to pain that may cause hospitalization and/or
cancer treatment interruptions if sufficiently severe.
In the phase II, randomized, double-blind, placebocontrolled study, Peterson and his colleagues tested an oral spray
containing recombinant human intestinal trefoil factor (rhITF)
administered for approximately two weeks during the period
of highest risk development of oral mucositis. They found the
spray to be safe and highly effective when used for the reduction
of chemotherapy-associated oral mucositis in patients with
colorectal cancer. Future clinical study is planned to develop
this drug for use in oral mucositis management in patients
undergoing high-dose cancer therapies. n

The Mysteries of Alternative Splicing

Next-Generation Sequencer

A

t first glance it appears to be just another laboratory slide,
a millimeter-thick rectangle 1.5 centimeters wide by
6.5 centimeters long. But when it’s examined against
a light source, a series of whispery parallel lines
becomes apparent. They are internal walls that
separate the slide into eight chambers each of
which is as narrow as angel hair pasta.
When Brenton Graveley, Ph.D., associate
professor of genetics and developmental
biology, inserts the slide into a squat device
called a cluster station, clear liquid is
injected through the almost imperceptibly
small holes at the ends of the chambers. The
slide is instantaneously transformed into a
library of information. The liquid injected into
the eight tiny chambers contains samples of genetic
material, chemically extracted from organic tissue. And
with the help of the Health Center’s powerful Illumina® Genome
Analyzer, Graveley will soon know the precise sequence of
genes in each sample.

UConn School of Medicine

“Soon” is the key word. In the Health Center’s Translational
Genomics Core, a center that provides a host of esoteric
services for monitoring gene and microRNA expression, the
sequencer is both a workhorse and a thoroughbred,
a brute for work and incredibly fast. While
sequencing technology has been around for
almost a quarter of a century, “next generation
sequencers” like this one are emphatically
21st century. To understand how rapidly –
and dramatically – they have revolutionized
genetic research, it is worth considering
how they would have impacted the Human
Genome Project.
Launched in 1990, when Graveley was
still a graduate student, that celebrated research
program occupied an army of researchers worldwide
who spent a full decade determining the sequence of
chemical base pairs that make up human DNA. For the record,
there are about three billion base pairs containing the 20,000
to 25,000 distinct genes that make up the 23-chromosome
human genome.

w

Part of what has made the new sequencers so popular are
scientific breakthroughs in the study of microRNAs and
alternative splicing that have significantly changed the research
picture in the nine years since the Human Genome Project
was completed. “As recently as the late 1990s, it was thought
that most human genes encoded only a single messenger
RNA (mRNA) isoform,” says Graveley. “Now we know that
alternative splicing is the rule, not the exception. In fact, 95
percent of human genes encode at least two isoforms and most
known alternative-splicing events are regulated.”
Graveley and his team are currently hard at work on one
line of related research. They are one of six teams at major
universities all over the U.S. participating in a project called
modENCODE, funded by the National Human Genome
Research Institute, part of the National Institutes of Health.
Researchers in the modENCODE project are trying to identify
the myriad alternative splicing pathways in the genomes
of Drosophila melanogaster, the common fruit fly, and
Caenorhabditis elegans, a tiny roundworm. The project is less
about those organisms than it is about the process of unraveling
the mysteries of their sequence-based functional elements.
Graveley’s team is working on the fruit fly, an insect that has
captivated his scientific imagination for years. “The Drosophila’s
genome is very compact and only about one-tenth the size of
the human genome,” he says. “That makes it very useful for this
research.”
Even so, completing the project – which involves studying
which genes are turned on and off at some 30 points over the
course of the fly’s short, two to three week lifespan – is expected
to take about four years, so complex are the twists and turns of
the fly’s genetic sequencing. Graveley’s team is about halfway
through. “When the project is complete, researchers expect to
know much more about how to tackle studying the much more
complex human genome. That task is expected to be wrapped
up by 2012.” n
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Gifts

Honors

Advocating for Advances in
Cancer Research and Care

Dr. Faryal Mirza Recognized for
Osteoporosis Research

C

T

arolyn D. Runowicz,
M.D., Director of the
Neag Comprehensive
Cancer Center continues
to be a national voice for
a range of cancer-related
issues, from increased
awareness about cancer
survivorship to advocacy
for more robust activity in
clinical research.
Since 2004, she has
served on the National
Cancer Advisory Board
(NCAB), and has held the role of chair since 2006. She is the
first gynecologic oncologist to hold this position. The role of
the NCAB is to advise the secretary of the U.S. Department of
Health and Human Services and the Director of the National
Cancer Institute with regard to its activities, including the
review and recommendation of support grants and cooperative
agreements. There are 18 members of the advisory board
which include leading representatives from health and science
disciplines; all are appointed by the president of the U.S.
In addition, Runowicz also serves as Chair of the Clinical
Research Committee for the American Society of Clinical
Oncology (ASCO), the world leading professional organization
representing physicians who treat people with cancer.
“Working with national organizations is a tremendous
opportunity to help all of us achieve strategic objectives
related to improvements in the prevention, early detection and
treatment of cancers,” said Runowicz who previously served as
President of the American Cancer Society. n

he American Society for Bone
and Mineral Research has
presented the 2009 ASBMR
Award for Most Outstanding
Research in the Pathophysiology
of Osteoporosis to Faryal Mirza,
M.D., an endocrinologist with the
New England Musculoskeletal
Institute.
Mirza was recognized for
her abstract of her study on the
role of sclerostin, a hormone
believed to inhibit bone
formation, in the development of postmenopausal osteoporosis. n

Dr. Philip P. Smith
Honored by American
Geriatrics Society

P

hilip P. Smith, M.D.,
head of the Center for
Continence and Voiding
Disorders is the recipient of
a Dennis W. Jahnigen Career
Development Scholars Award
from the American Geriatrics
Society.
The Jahnigen Career
Development Scholars Awards
Program provides two-year grants of $200,000, including
an institutional match, to assist young faculty as they initiate
and ultimately sustain a career in research and education in
the geriatrics aspects of their discipline. Smith is the only
2009 Jahnigen scholar from Connecticut and one of seven
nationwide. The grant will support his research in the area of
lower urinary tract function in old age under the mentorship
of Peter Albertsen, M.D., chief of the UConn Division of
Urology, and George A. Kuchel, M.D., director of the UConn
Center on Aging.
An abstract of Smith’s winning proposal is available at
http://www.americangeriatrics.org/hartford/2009_Jahnigen_
Career_Development_Scholars.shtml#smith. n

Fast Fact

22

Years UConn medical students
have been providing primary care
and counseling to Hartford’s homeless
at the South Park Inn Medical Clinic.

UConn School of Medicine

Department of Dermatology Highlights
Fundraising Efforts

y

L

ocated in a new, larger facility, and fresh from recruiting a new
research expert through the support of private giving, the
Department of Dermatology is also celebrating two major gifts.
A pledge of $100,000 from Jane M. Grant-Kels, M.D., chair
of the department, and her husband, Barry D. Kels, J.D., M.D.,
executive director of risk management has been matched dollarfor-dollar by an anonymous donor, a grateful patient of Grant-Kels.
“The support shown by Jane and Barry, as well as our grateful
patients at the Health Center, is a testament to the generosity and
commitment of those most personally connected to the UConn
Health Center,” says Cato T. Laurencin, M.D., Ph.D., vice president
for health affairs.
The gifts are part of an upcoming sustained fundraising effort
for the department, which includes the preliminary goal of a
$3-million distinguished endowed department head chair in
melanoma and cutaneous oncology or psoriasis.
In addition, the department recently recruited a leading
researcher to the cutaneous oncology program, partially supported
through funds raised by the (2007) Imagine gala.
Soheil Sam Dadras, M.D., Ph.D., a specialist in cutaneous
melanoma, has joined the research team at the Health Center.
Grant-Kels says that his addition shows the power that private
giving can have in elevating research efforts at the University. n

Cato T. Laurencin, M.D., Ph.D., in his research lab with a group of scientists for
whom he serves as mentor

Mentoring, Mother’s Professional
Influence Leads to Laurencin’s
Lifetime of Success

H

is career has taken him to the forefront of musculoskeletal
care and research, recognition by the White House,
national prominence in his field, and the helm of the
UConn Health Center as the vice president for health affairs.
However, the inspiration that started Cato T. Laurencin, M.D.,
Ph.D., down the road of medicine was provided by his mother,
who operated a clinical practice and research laboratory on the
first floor of the family’s row house in North Philadelphia.
It is in her name and honor that Laurencin and his wife,
Cynthia, have now created a fellowship for UConn School
of Medicine students. The Helen I. Moorehead-Laurencin,
M.D. Research Fellowship Fund supports students who have
demonstrated academic achievement and are involved in
conducting summer research projects. He says the emphasis
on research perfectly matches his mother’s passion for
understanding the science of medicine.
The fellowship addresses the other area of focus of
Moorehead-Laurencin’s life: ensuring that young people have
a mentor. Recipients must provide mentorship to an inner city
high school student in the Hartford region. Laurencin says
that his mother sought out and assisted young people in their
neighborhood, encouraged them to pursue careers in medicine
and science, and counseled those around her.
In addition to contributing a major gift to create the fund,
Laurencin will also utilize an additional $10,000 presented to
him as a recipient of the 2009 Presidential Awards for
Excellence for supporting student research experiences. n

Jane M. Grant-Kels, M.D., chair of the Department of Dermatology

z

Winter 2010

Gifts

Honors

Advocating for Advances in
Cancer Research and Care

Dr. Faryal Mirza Recognized for
Osteoporosis Research

C
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arolyn D. Runowicz,
M.D., Director of the
Neag Comprehensive
Cancer Center continues
to be a national voice for
a range of cancer-related
issues, from increased
awareness about cancer
survivorship to advocacy
for more robust activity in
clinical research.
Since 2004, she has
served on the National
Cancer Advisory Board
(NCAB), and has held the role of chair since 2006. She is the
first gynecologic oncologist to hold this position. The role of
the NCAB is to advise the secretary of the U.S. Department of
Health and Human Services and the Director of the National
Cancer Institute with regard to its activities, including the
review and recommendation of support grants and cooperative
agreements. There are 18 members of the advisory board
which include leading representatives from health and science
disciplines; all are appointed by the president of the U.S.
In addition, Runowicz also serves as Chair of the Clinical
Research Committee for the American Society of Clinical
Oncology (ASCO), the world leading professional organization
representing physicians who treat people with cancer.
“Working with national organizations is a tremendous
opportunity to help all of us achieve strategic objectives
related to improvements in the prevention, early detection and
treatment of cancers,” said Runowicz who previously served as
President of the American Cancer Society. n

he American Society for Bone
and Mineral Research has
presented the 2009 ASBMR
Award for Most Outstanding
Research in the Pathophysiology
of Osteoporosis to Faryal Mirza,
M.D., an endocrinologist with the
New England Musculoskeletal
Institute.
Mirza was recognized for
her abstract of her study on the
role of sclerostin, a hormone
believed to inhibit bone
formation, in the development of postmenopausal osteoporosis. n

Dr. Philip P. Smith
Honored by American
Geriatrics Society

P

hilip P. Smith, M.D.,
head of the Center for
Continence and Voiding
Disorders is the recipient of
a Dennis W. Jahnigen Career
Development Scholars Award
from the American Geriatrics
Society.
The Jahnigen Career
Development Scholars Awards
Program provides two-year grants of $200,000, including
an institutional match, to assist young faculty as they initiate
and ultimately sustain a career in research and education in
the geriatrics aspects of their discipline. Smith is the only
2009 Jahnigen scholar from Connecticut and one of seven
nationwide. The grant will support his research in the area of
lower urinary tract function in old age under the mentorship
of Peter Albertsen, M.D., chief of the UConn Division of
Urology, and George A. Kuchel, M.D., director of the UConn
Center on Aging.
An abstract of Smith’s winning proposal is available at
http://www.americangeriatrics.org/hartford/2009_Jahnigen_
Career_Development_Scholars.shtml#smith. n
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Coming Soon:
A Center of Innovation

he University of Connecticut is
establishing a center of innovation that
will include its world-renowned Stem
Cell Institute and Center for Cell Analysis
and Modeling as well as cutting edge
genetics and genomics research. The $52
million, 117,000 sq. ft. Cell and Genome
Sciences building will be equipped with
the latest technologies for studying stem
cells and their genomes. The new center

will unite UConn scientists in a crossdisciplinary, collaborative setting to enhance
Connecticut’s role as a leader in biomedical
research and accelerate discoveries that
ultimately could lead to therapies treating
a broad range of diseases and disorders.
Situated on 24 acres of land near the Health
Center campus, the renovation is expected
to be completed by the summer of 2010.

